ClinicalTrials.gg
CompletedNCT01964430apactUpdated Jun 28, 2023Results posted

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

A Phase 3 interventional study of nab-Paclitaxel and Gemcitabine in Pancreatic Neoplasms, Digestive System Neoplasms and Neoplasms by Site, sponsored by Celgene. Completed at 341 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
866
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.

Enrollment
4th of 130
866 · median 47
Started
2014
with 13 others
Phase 3
8 of 130
4 open now
Registered
14th of 130
by date
Lead sponsor
8 of 130
Celgene

Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 4th largest by enrollment, is one of 14 that started in 2014, is one of 8 in phase 3, and was the 14th registered.

Pancreatic Neoplasms

3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone.

Read the detailed description

ABI-007-PANC-003 is a Phase 3, international, multicenter, randomized, open-label, controlled study that will compare the efficacy of nab-paclitaxel in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 cycles in patients with surgically resected pancreatic adenocarcinoma.

03

Conditions studied

  • Pancreatic Neoplasms
  • Digestive System Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Endocrine Gland Neoplasms
  • Pancreatic Diseases
  • Digestive System Diseases
  • Endocrine System Diseases
  • Gemcitabine
  • Antimetabolites, Antineoplastic

Keywords

  • Resectable pancreatic cancer
  • resected
  • resectable PDA
  • adenocarcinoma
  • surgically resected
  • adjuvant
  • Abraxane
  • nab-paclitaxel
  • ABI-007
  • gemcitabine
  • Gemzar
  • Phase 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). Subjects with neuroendocrine (and mixed type) tumors are excluded.
  2. Pancreatic cancer surgical staging: Tumor (T) 1-3, Lymph Node (LN) N0-1, (M) 0.
  3. Subject should be able to start treatment no later than 12 weeks postsurgery.
  4. ≥18 years of age at the time of signing the form (ICF).
  5. (ECOG) performance status of 0 or 1.
  6. Acceptable hematology parameters:

    • (ANC) ≥1500 cell/mm\^3
    • count ≥100,000/mm\^3
    • (Hgb) ≥9 g/dL
  7. Acceptable blood chemistry levels:

    • (AST)/ serum glutamic oxaloacetic transaminase (SGOT) and alanine transaminase (ALT)/ serum glutamic -pyruvic transaminase (SGPT) ≤2.5 × (ULN)
    • Total ≤ upper limit of normal (participants with Gilbert's syndrome can have bilirubin of up to 1.5 x ULN)
    • Alkaline phosphatase ≤ 2.5 x ULN
    • Serum creatinine within upper limits of normal or calculated clearance ≥50 mL/min/1.73 m\^2. If using , actual body weight should be used for calculating creatinine clearance (eg, using the Cockroft-Gault formula). For subjects with a (BMI) >30 kg/m2, lean body weight should be used instead
  8. Cancer antigen (CA)19-9 \<100 U/mL assessed within 14 days of randomization
  9. Acceptable coagulation studies as demonstrated by (PT) and partial thromboplastin time (PTT) within normal limits (±15%)

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Prior treatment or radiation therapy for pancreatic adenocarcinoma
  2. Presence of or history of pancreatic adenocarcinoma
  3. Any other within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, or nonmelanomatous skin cancer (all treatment of which should have been completed 6 months prior to randomization)
  4. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
  5. Known infection with or C, or history of (HIV) infection, or subject receiving or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications
  6. History of allergy or to nab-paclitaxel or gemcitabine or any of their
  7. Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity. These include, but are not limited to:

    1. History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa)
    2. History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
    3. History of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, (NYHA) Class III-IV heart failure, uncontrolled hypertension, cardiac dysrhythmia or (ECG) abnormality, cerebrovascular accident, , or seizure disorder
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
866 participants (actual)

Study arms

  • Experimental
    nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2

    Participants received nab-Paclitaxel 125 mg/m\^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m\^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.

    Drug: nab-Paclitaxel · Drug: Gemcitabine

  • Active comparator
    Gemcitabine 1000 mg/m^2

    Participants received gemcitabine 1000 mg/m\^2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.

    Drug: Gemcitabine

Interventions

  • nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.

    Also known as: Abraxane

  • Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee

    Disease free survival was defined as the time from the date of randomization to the date of disease recurrence or death, whichever occurred earlier. Disease recurrence was determined by the independent radiological review of computed tomography (CT) or magnetic resonance imaging (MRI) scans. Participants who did not have disease recurrence or did not die were censored at the last tumor assessment date with disease-free status or the randomization date if the last tumor assessment with disease-free status was missing. Disease-free status referred to a status that was neither being disease recurrent nor indeterminate or not evaluable. Participants who received new anti-cancer therapy or cancer-related surgery prior to disease recurrence or death were censored at the date of last tumor assessment with disease-free status prior to the start of new anti-cancer therapy or cancer-related surgery or the randomization date.

    Time frame: Date of randomization up to data cut off date of 31 December 2018; median DFS follow-up time for censored participants was 22.242 months for nab-Paclitaxel and gemcitabine and 13.832 months for gemcitabine alone

Secondary outcomes

  1. Kaplan Meier Estimate of Overall Survival (OS)

    Overall survival was defined as the time from the date of randomization to the date of death. Participants who were alive at the end of study or clinical data cut were censored on the last-known-to-be-alive date or the clinical cutoff date, whichever was earlier.

    Time frame: From randomization to date of death; median OS follow-up time for censored participants was 77.832 months for nab-Paclitaxel and gemcitabine and 77.799 months for gemcitabine alone

  2. Number of Participants With Treatment Emergent Adverse Events (TEAE's)

    TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to one or both of the study drugs and reported as 'Suspected' on the case report form. AEs with a missing relationship were treated as 'treatment-related' in data summaries. IP (investigational product) refers to nab-Paclitaxel and/or Gemcitabine. "Related" TEAE refers to relation to study drug (IP).

    Time frame: From day 1 of study drug up to 28 days after the last dose of study drug; up to the data cut off date of 31 December 2018 (up to approximately 37 weeks).

  3. The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4)

    The number of participants with grade 3-4 laboratory abnormalities in selected clinically significant parameters. Grades for chemistry parameters were coded using National Cancer Institute Common Terminology Criteria for Adverse Events (Grade 3= severe, Grade 4= life-threatening).

    Time frame: From day 1 of study drug up to 28 days after the last dose of study drug, or the treatment discontinuation date, whichever was later (up to approximately 37 weeks).

07

Results

Posted Jan 6, 2020

Participant flow

The study randomized participants at 160 sites in 21 countries: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Italy, Netherlands, Portugal, Singapore, Republic of Korea, Spain, Taiwan, United Kingdom and the US.

Pre-Treatment (Randomization) Period
Participant flow — Pre-Treatment (Randomization) Period
MilestoneNab-Paclitaxel and GemcitabineGemcitabine
Started432434
Completed429423
Not completed311
Withdrew: Protocol deviation02
Withdrew: Withdrawal by subject29
Withdrew: Adverse event10
Treatment Period
Participant flow — Treatment Period
MilestoneNab-Paclitaxel and GemcitabineGemcitabine
Started429423
Completed287310
Not completed142113
Withdrew: Adverse event7137
Withdrew: Withdrawal by subject3627
Withdrew: Death13
Withdrew: Protocol deviation01
Withdrew: Physician decision54
Withdrew: Disease relapse2838
Withdrew: Other reasons13

Outcome measures

PrimaryKaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee

Disease free survival was defined as the time from the date of randomization to the date of disease recurrence or death, whichever occurred earlier. Disease recurrence was determined by the independent radiological review of computed tomography (CT) or magnetic resonance imaging (MRI) scans. Participants who did not have disease recurrence or did not die were censored at the last tumor assessment date with disease-free status or the randomization date if the last tumor assessment with disease-free status was missing. Disease-free status referred to a status that was neither being disease recurrent nor indeterminate or not evaluable. Participants who received new anti-cancer therapy or cancer-related surgery prior to disease recurrence or death were censored at the date of last tumor assessment with disease-free status prior to the start of new anti-cancer therapy or cancer-related surgery or the randomization date.

Time frame:
Date of randomization up to data cut off date of 31 December 2018; median DFS follow-up time for censored participants was 22.242 months for nab-Paclitaxel and gemcitabine and 13.832 months for gemcitabine alone
Reported as:
Median · months
Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee
monthsNab-Paclitaxel and GemcitabineGemcitabine
Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee19.4 (16.62 to 21.91)18.8 (13.83 to 20.30)
Statistical analysis
  • Nab-Paclitaxel and Gemcitabine vs Gemcitabine · Log Rank · p = 0.1824 · Hazard ratio (hr): 0.88 · 95% CI 0.729 to 1.063Estimated using stratified Cox proportional hazards model adjusting for strata of resection status (R0 versus R1) and nodal status (LN+ versus LN-).
SecondaryKaplan Meier Estimate of Overall Survival (OS)

Overall survival was defined as the time from the date of randomization to the date of death. Participants who were alive at the end of study or clinical data cut were censored on the last-known-to-be-alive date or the clinical cutoff date, whichever was earlier.

Time frame:
From randomization to date of death; median OS follow-up time for censored participants was 77.832 months for nab-Paclitaxel and gemcitabine and 77.799 months for gemcitabine alone
Reported as:
Median · months
Kaplan Meier Estimate of Overall Survival (OS)
monthsNab-Paclitaxel and GemcitabineGemcitabine
25th Quartile20.7 (19.38 to 22.83)17.7 (14.78 to 19.91)
50th Quartile41.8 (35.55 to 47.28)37.7 (31.11 to 40.51)
75th Quartile90.2 (83.55 to NA)83.0 (61.93 to NA)
Statistical analysis
  • Nab-Paclitaxel and Gemcitabine vs Gemcitabine · Log Rank · p = 0.0128 · Hazard ratio (hr): 0.81 · 95% CI 0.691 to 0.957Estimated using stratified Cox proportional hazards model adjusting for strata of resection status (R0 versus R1) and nodal status (LN+ versus
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE's)

TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to one or both of the study drugs and reported as 'Suspected' on the case report form. AEs with a missing relationship were treated as 'treatment-related' in data summaries. IP (investigational product) refers to nab-Paclitaxel and/or Gemcitabine. "Related" TEAE refers to relation to study drug (IP).

Time frame:
From day 1 of study drug up to 28 days after the last dose of study drug; up to the data cut off date of 31 December 2018 (up to approximately 37 weeks).
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE's)
ParticipantsNab-Paclitaxel and GemcitabineGemcitabine
≥1 TEAE429417
≥1 Related TEAE423399
≥1 TEAE of Severity Grade 3 or Higher371286
≥ 1 Related TEAE of Severity Grade 3 or Higher332239
≥1 Serious TEAE17696
≥1 Serious Related TEAE10255
≥1 TEAE Leading to Withdrawal of IP11743
≥1 Related TEAE Leading to Withdrawal of IP9835
≥1 TEAE Lead Dose Reduction: nab-Paclitaxel or Gem276210
≥1 Related TEAE Dose Reduct: nab-Paclitaxel or Gem270205
TEAE Lead Dose Interruption nab-Paclitaxel or Gem266158
≥1 Related TEAE Dose Interruption to IP221125
TEAE Leading to Death22
>=1 Related TEAE Leading to Death22
SecondaryThe Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4)

The number of participants with grade 3-4 laboratory abnormalities in selected clinically significant parameters. Grades for chemistry parameters were coded using National Cancer Institute Common Terminology Criteria for Adverse Events (Grade 3= severe, Grade 4= life-threatening).

Time frame:
From day 1 of study drug up to 28 days after the last dose of study drug, or the treatment discontinuation date, whichever was later (up to approximately 37 weeks).
Reported as:
Count of participants · Participants
The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4)
ParticipantsNab-Paclitaxel and GemcitabineGemcitabine
Alkaline phosphatase73
Alanine aminotransferase93
Aspartate aminotransferase92
Bilirubin01

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 94 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 46 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nab-Paclitaxel and Gemcitabine285/432 (66%)181/429 (42.2%)426/429 (99.3%)
Gemcitabine297/434 (68.4%)96/423 (22.7%)407/423 (96.2%)
Most frequent serious events
Showing 10 of 216
Most frequent serious events
EventNab-Paclitaxel and GemcitabineGemcitabine
PyrexiaGeneral disorders29/42924/423
Febrile neutropeniaBlood and lymphatic system disorders16/4293/423
AnaemiaBlood and lymphatic system disorders12/4296/423
DiarrhoeaGastrointestinal disorders12/4290/423
SepsisInfections and infestations12/4295/423
InfectionInfections and infestations9/4291/423
PneumoniaInfections and infestations9/4296/423
VomitingGastrointestinal disorders8/4290/423
CellulitisInfections and infestations8/4295/423
DehydrationMetabolism and nutrition disorders8/4292/423
Most frequent other events
Showing 10 of 55
Most frequent other events
EventNab-Paclitaxel and GemcitabineGemcitabine
NeutropeniaBlood and lymphatic system disorders263/429230/423
AlopeciaSkin and subcutaneous tissue disorders252/42952/423
DiarrhoeaGastrointestinal disorders242/429125/423
FatigueGeneral disorders233/429203/423
NauseaGastrointestinal disorders231/429192/423
AnaemiaBlood and lymphatic system disorders179/429142/423
PyrexiaGeneral disorders171/429115/423
Oedema peripheralGeneral disorders162/429108/423
Peripheral sensory neuropathyNervous system disorders144/42916/423
Decreased appetiteMetabolism and nutrition disorders143/42984/423

Baseline characteristics

The Intent-to-treat (ITT) population consisted of all randomized participants regardless of whether the participant received any investigational product (IP) or had any efficacy assessments collected.

Age, Continuous
Age, Continuous(Years)Nab-Paclitaxel and GemcitabineGemcitabineTotal
Mean63.4 ± 9.5862.9 ± 8.8463.2 ± 9.21
Sex: Female, Male
Sex: Female, Male(Participants)Nab-Paclitaxel and GemcitabineGemcitabineTotal
Female204181385
Male228253481
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nab-Paclitaxel and GemcitabineGemcitabineTotal
Hispanic or Latino111526
Not Hispanic or Latino400393793
Unknown or Not Reported212647
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nab-Paclitaxel and GemcitabineGemcitabineTotal
American Indian or Alaska Native011
Asian6056116
Black or African American4812
Native Hawaiian or Other Pacific Islander022
White333339672
Other11617
Not Collected or Reported242246
Region of Enrollment
Region of Enrollment(Participants)Nab-Paclitaxel and GemcitabineGemcitabineTotal
North America144156300
Europe203205408
Australia302050
Asia Pacific5553108
Body Surface Area (BSA)
Body Surface Area (BSA)(m²)Nab-Paclitaxel and GemcitabineGemcitabineTotal
Mean1.77 ± 0.2261.78 ± 0.2211.78 ± 0.224
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Nab-Paclitaxel and GemcitabineGemcitabineTotal
0 = Fully Active252268520
1 = Restricted but Ambulatory180166346
2 = Ambulatory but Unable to Work000
3 = Limited Self-care000
4 = Completely Disabled000
Physician Assessment of Peripheral Neuropathy
Physician Assessment of Peripheral Neuropathy(Participants)Nab-Paclitaxel and GemcitabineGemcitabineTotal
Grade 0404408812
Grade 1262147
Grade 2011
Grade 3000
Grade 4000
Missing246

4 further baseline measures are reported on the registry.

08

Study locations

341 sites
  • Local Institution - 043
    Scottsdale, Arizona 85259, United States
  • Mayo Clinic - Arizona
    Scottsdale, Arizona 85259, United States
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Local Institution - 044
    Sacramento, California 95817, United States
  • UC Davis Cancer Center
    Sacramento, California 95817, United States
  • Local Institution - 001
    San Francisco, California 94110, United States
  • University of California, San Francisco Cutaneous Oncology and Melanoma Center
    San Francisco, California 9411, United States
  • University of California Los Angeles
    Santa Monica, California 90404, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Local Institution - 059
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers, LLP [Denver-Midtown]
    Denver, Colorado 80218, United States
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • Local Institution - 022
    Boca Raton, Florida 33486, United States
  • Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Florida Cancer Institute Cancer Spec
    Fort Myers, Florida 33916, United States
  • Local Institution - 031
    Fort Myers, Florida 33916, United States
  • Gainesville Heme Oncology Associates
    Gainesville, Florida 32605, United States
  • Local Institution - 011
    Gainesville, Florida 32610, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Miami and Sylvester Cancer Center
    Miami, Florida 33136, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Local Institution - 039
    Orlando, Florida 32804, United States
  • H Lee Moffitt Cancer Center
    Tampa, Florida 32207, United States
  • Georgia Cancer Specialist
    Atlanta, Georgia 30341, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Northshore University Healthsystem Research Institute
    Evanston, Illinois 60201, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121-2483, United States
  • Ochsner Medical Center - Jefferson Highway
    New Orleans, Louisiana 70121-2483, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel-Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Local Institution - 040
    Boston, Massachusetts 02115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Local Institution - 045
    Boston, Massachusetts 02215, United States
  • Local Institution - 036
    Ann Arbor, Michigan 48109, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Center Wayne State University
    Detroit, Michigan 48201, United States
  • Local Institution - 021
    Rochester, Minnesota 55905, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Local Institution - 048
    Omaha, Nebraska 68114, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Local Institution - 064
    Basking Ridge, New Jersey 07920, United States
  • MSKCC Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • Local Institution - 025
    Buffalo, New York 14263, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan-Kettering Cancer Center
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center West Harrison
    Harrison, New York 10604, United States
  • NYU Langone Medical Center
    Lake Success, New York 11042, United States
  • Local Institution - 008
    New York, New York 10021-6007, United States
  • Memorial Sloan-Kettering Cancer Center - NYC
    New York, New York 10021-6007, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Local Institution - 032
    New York, New York 10032, United States
  • Local Institution - 013
    Rochester, New York 14642, United States
  • University of Rochester Cancer Center, James P. Wilmot Cancer Center
    Rochester, New York 14642, United States
  • Local Institution - 066
    Rockville Center, New York 11570, United States
  • MSKCC at Mercy Medical Center Mercy RockvilleCenter
    Rockville Center, New York 11570, United States
  • MSKCC at Phelps Memorial Hospital Center. Phelps Sleepy Hollow
    Sleepy Hollow, New York 10591, United States
  • State University of New York Upstate Medical Center
    Syracuse, New York 13215, United States
  • Local Institution - 051
    Winston-Salem, North Carolina 27157-1082, United States
  • Wake Forest Univ. Health Sciences Outpatient Comprehensive Cancer Center
    Winston-Salem, North Carolina 27157-1082, United States
  • Local Institution - 030
    Cincinnati, Ohio 45242, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • University of Cincinnati Medical CenterDivsion of Hematology OncologyThe Barrett Center
    Cincinnati, Ohio 45267-0501, United States
  • Case Western Reserve Center
    Cleveland, Ohio 44106, United States
  • Local Institution - 047
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic - Taussig Cancer Institute
    Cleveland, Ohio 44195, United States
  • Cleveland Clinic Foundation IRB
    Cleveland, Ohio 44195, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Local Institution - 020
    Cleveland, Ohio 44195, United States
  • Local Institution - 054
    Cleveland, Ohio 44195, United States
  • Local Institution - 005
    Columbus, Ohio 43210, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Local Institution - 049
    Oklahoma City, Oklahoma 73104, United States
  • University of Oklahoma Peggy and Charles Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution - 019
    Portland, Oregon 97239, United States
  • Oregon Health and Science University OHSU
    Portland, Oregon 97239, United States
  • Local Institution - 016
    Philadelphia, Pennsylvania 19107, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Local Institution - 027
    Pittsburgh, Pennsylvania 15232, United States
  • UPMC Cancer Pavillion
    Pittsburgh, Pennsylvania 15232, United States
  • Chattanooga Oncology Hematology Care
    Chattanooga, Tennessee 37404, United States
  • Local Institution - 023
    Chattanooga, Tennessee 37404, United States
  • Local Institution - 004
    Nashville, Tennessee 37203, United States
  • Sarah Cannon Research Inst
    Nashville, Tennessee 37203, United States
  • Local Institution - 002
    Nashville, Tennessee 37232-6307, United States
  • Vanderbilt- Ingram Cancer Center
    Nashville, Tennessee 37232-6307, United States
  • Texas Oncology
    Dallas, Texas 75230, United States
  • Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Local Institution - 062
    Dallas, Texas 75246, United States
  • Local Institution - 010
    Dallas, Texas 75390, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Local Institution - 050
    Fort Worth, Texas 76104, United States
  • The Center for Cancer and Blood Disorders - Fort Worth
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Local Institution - 041
    Houston, Texas 77030, United States
  • Texas Oncology, P.A. - Tyler
    Tyler, Texas 75702, United States

Showing the first 100 of 341 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Young R, Mainwaring P, Clingan P, Parnis FX, Asghari G, Beale P, Aly A, Botteman M, Romano A, Ferrara S, Margunato-Debay S, Harris M. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Asia Pac J Clin Oncol. 2018 Oct;14(5):e325-e331. doi: 10.1111/ajco.12999. Epub 2018 Jun 22. PubMed 29932294 ↗
  • Reni M, Zanon S, Balzano G, Passoni P, Pircher C, Chiaravalli M, Fugazza C, Ceraulo D, Nicoletti R, Arcidiacono PG, Macchini M, Peretti U, Castoldi R, Doglioni C, Falconi M, Partelli S, Gianni L. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018 Oct;102:95-102. doi: 10.1016/j.ejca.2018.07.007. Epub 2018 Aug 24. PubMed 30149366 ↗
  • Fernandez A, Salgado M, Garcia A, Buxo E, Vera R, Adeva J, Jimenez-Fonseca P, Quintero G, Llorca C, Canabate M, Lopez LJ, Munoz A, Ramirez P, Gonzalez P, Lopez C, Reboredo M, Gallardo E, Sanchez-Canovas M, Gallego J, Guillen C, Ruiz-Miravet N, Navarro-Perez V, De la Camara J, Ales-Diaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3. PubMed 30497432 ↗
  • Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, Reni M, Li CP, O'Neil B, Van Cutsem E, Bekaii-Saab T. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019 Apr;15(12):1295-1302. doi: 10.2217/fon-2018-0903. Epub 2019 Feb 15. PubMed 30768369 ↗
  • Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Nov;28(12):7545-7554. doi: 10.1245/s10434-021-09816-z. Epub 2021 Apr 3. PubMed 33813673 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jun 2022, 99 months.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's 99 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2013
First posted
Oct 17, 2013
StartActual
Mar 28, 2014
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Results first posted
Jan 6, 2020
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01964430
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 17, 2013
Start date
Mar 28, 2014
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Results posted
Jan 6, 2020
Last update
Jun 28, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion